New study suggests weight loss drugs like Ozempic could help with knee pain. Here’s why there may be a link
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and osteoarthritis.
FDA adds new warning to weight loss drugs including Wegovy
The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under anesthesia.
What are your questions about weight loss drugs?
Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight management but for many people, there are still questions around side effects, accessibility and results.
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Counterfeit weight loss drugs feed demand for cheaper options
A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable online pharmacies in search of weight loss drugs at a discounted price.
Weight-loss drugs can help stroke survivors prevent recurrence
The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.
Wegovy and other weight loss drugs shows promise for heart disease
A new clinical trial found that weight-loss drug Wegovy shows promise for lowering the risk of heart attack and stroke among people with heart disease and obesity.
Weight-loss drugs just got cheaper — and better
Eli Lilly priced its new weight-loss drug Zepbound 20% lower than competitor Wegovy, an unusual move in the pharmaceutical world.
FDA adds new warning to weight loss drugs
The U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents
Ozempic butt: A side effect of this popular diabetes and weight loss drug
Ozempic has been talk of the town for a while now, not only for helping people with diabetes, but also for working as a weight loss drug. Global celebrities like Amy Schumer, Sharon Osbourne, and Kathy Bates have admitted to using this medication to drop extra pounds.
Hosted on MSN1d
Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, ...
Yahoo17h
Dr. Todd Ellerin on the effects of popular weight-loss drug Wegovy
Dr. Todd Ellerin, Vice Chair of Medicine at South Shore Health, talks to WCVB's Ed Harding about the effects popular weight ...
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
Daily Journal21h
Franciscan doctors to host discussion on weight-loss drugs, health
A special event is aimed at answering questions and giving local residents the best information about those medications.
Healthline1d
Ozempic and Wegovy May Provide Strong Relief from Osteoarthritis Knee Pain
Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.
WSB Radio18h
Could drugs like Ozempic help with substance abuse disorders? Here’s what we found
Ozempic and Wegovy Popular drugs like Ozempic and Wegovy are known for dramatic weight loss, but they also can ...
Ozempic’s maker wants the US government to ban cheaper versions of the high-priced $969 injection weight-loss drug – claims the formula is ‘too complex’ to cop…
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...